---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-24-000025"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:59:16.958736+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Gilead Q3 revenue up 7% to $7.5B; raises full-year guidance

## Summary
- GAAP EPS $1.00 (down from $1.73) due to $1.75B Immunomedics IPR&D impairment; Non-GAAP EPS $2.02 vs $2.29.
- Biktarvy sales $3.5B (+13% YoY); HIV product sales $5.1B (+9%); Trodelvy $332M (+17%).
- Full-year product sales guidance raised to $27.8-28.1B (from $27.1-27.5B); Non-GAAP EPS raised to $4.25-4.45 from $3.60-3.90.
- Operating cash flow $4.3B in Q3; paid $983M dividends and repurchased $300M stock.
- Oncology sales $816M (+6%); Cell therapy sales $485M flat YoY.

## SEC filing metadata
- accession: 0000882095-24-000025
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209524000025/0000882095-24-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209524000025/gild-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-24-000025
- JSON: https://secwatch.observer/filing/0000882095-24-000025.json
- Plain text: https://secwatch.observer/filing/0000882095-24-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.